Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status

Yoon Jin Cha, Hye Ryun Kim, Chang Young Lee, ByoungChul Cho, Hyo Sup Shim

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Introduction: PD-L1 expression is a predictive biomarker for response to anti-programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) immune checkpoint inhibitors and can be evaluated by immunohistochemistry. Results of the clinicopathologic characteristics of PD-L1-positive lung adenocarcinoma have been inconsistent in previous studies, and there are no reports on the relationship between PD-L1 expression and p53 status in lung adenocarcinoma. Methods: We examined PD-L1 and p53 expression in a total of 323 surgically resected lung adenocarcinoma cases using anti-PD-L1 (clone SP142) and anti-p53 (clone DO-7) antibodies, and analyzed the clinicopathologic characteristics of PD-L1-positive cases and their relationship with p53 status. Results: PD-L1 expression in tumor cells was positive in 60 of 323 cases (18.6%). Higher PD-L1 expression (≥50%) was more prevalent in former or current smokers (p = 0.026) and was associated with more pack-years (p = 0.016). PD-L1-positive tumors were significantly associated with solid predominant type (p < 0.001), p53 aberrant expression (p < 0.001), and PD-L1 expression in tumor-infiltrating immune cells (p < 0.001). Patients with stage I to III tumors harboring PD-L1-positive tumor cells showed poor recurrence-free survival (p < 0.001) and overall survival (p < 0.001) on univariate analysis. Conclusions: PD-L1 expression in tumor cells, solid predominant histology, p53 aberrant expression, and PD-L1 expression in tumor-infiltrating immune cells are closely related. These variables should be considered when analyzing the clinical outcomes of patients with lung adenocarcinomas treated with anti-PD1/PD-L1 immune checkpoint inhibitors.

Original languageEnglish
Pages (from-to)73-80
Number of pages8
JournalLung Cancer
Volume97
DOIs
Publication statusPublished - 2016 Jul 1

Fingerprint

CD274 Antigen
Cell Death
Ligands
Neoplasms
Adenocarcinoma of lung
Clone Cells

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

@article{805d27b82ede4d1590259235954ec9d2,
title = "Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status",
abstract = "Introduction: PD-L1 expression is a predictive biomarker for response to anti-programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) immune checkpoint inhibitors and can be evaluated by immunohistochemistry. Results of the clinicopathologic characteristics of PD-L1-positive lung adenocarcinoma have been inconsistent in previous studies, and there are no reports on the relationship between PD-L1 expression and p53 status in lung adenocarcinoma. Methods: We examined PD-L1 and p53 expression in a total of 323 surgically resected lung adenocarcinoma cases using anti-PD-L1 (clone SP142) and anti-p53 (clone DO-7) antibodies, and analyzed the clinicopathologic characteristics of PD-L1-positive cases and their relationship with p53 status. Results: PD-L1 expression in tumor cells was positive in 60 of 323 cases (18.6{\%}). Higher PD-L1 expression (≥50{\%}) was more prevalent in former or current smokers (p = 0.026) and was associated with more pack-years (p = 0.016). PD-L1-positive tumors were significantly associated with solid predominant type (p < 0.001), p53 aberrant expression (p < 0.001), and PD-L1 expression in tumor-infiltrating immune cells (p < 0.001). Patients with stage I to III tumors harboring PD-L1-positive tumor cells showed poor recurrence-free survival (p < 0.001) and overall survival (p < 0.001) on univariate analysis. Conclusions: PD-L1 expression in tumor cells, solid predominant histology, p53 aberrant expression, and PD-L1 expression in tumor-infiltrating immune cells are closely related. These variables should be considered when analyzing the clinical outcomes of patients with lung adenocarcinomas treated with anti-PD1/PD-L1 immune checkpoint inhibitors.",
author = "Cha, {Yoon Jin} and Kim, {Hye Ryun} and Lee, {Chang Young} and ByoungChul Cho and Shim, {Hyo Sup}",
year = "2016",
month = "7",
day = "1",
doi = "10.1016/j.lungcan.2016.05.001",
language = "English",
volume = "97",
pages = "73--80",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",

}

Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status. / Cha, Yoon Jin; Kim, Hye Ryun; Lee, Chang Young; Cho, ByoungChul; Shim, Hyo Sup.

In: Lung Cancer, Vol. 97, 01.07.2016, p. 73-80.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status

AU - Cha, Yoon Jin

AU - Kim, Hye Ryun

AU - Lee, Chang Young

AU - Cho, ByoungChul

AU - Shim, Hyo Sup

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Introduction: PD-L1 expression is a predictive biomarker for response to anti-programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) immune checkpoint inhibitors and can be evaluated by immunohistochemistry. Results of the clinicopathologic characteristics of PD-L1-positive lung adenocarcinoma have been inconsistent in previous studies, and there are no reports on the relationship between PD-L1 expression and p53 status in lung adenocarcinoma. Methods: We examined PD-L1 and p53 expression in a total of 323 surgically resected lung adenocarcinoma cases using anti-PD-L1 (clone SP142) and anti-p53 (clone DO-7) antibodies, and analyzed the clinicopathologic characteristics of PD-L1-positive cases and their relationship with p53 status. Results: PD-L1 expression in tumor cells was positive in 60 of 323 cases (18.6%). Higher PD-L1 expression (≥50%) was more prevalent in former or current smokers (p = 0.026) and was associated with more pack-years (p = 0.016). PD-L1-positive tumors were significantly associated with solid predominant type (p < 0.001), p53 aberrant expression (p < 0.001), and PD-L1 expression in tumor-infiltrating immune cells (p < 0.001). Patients with stage I to III tumors harboring PD-L1-positive tumor cells showed poor recurrence-free survival (p < 0.001) and overall survival (p < 0.001) on univariate analysis. Conclusions: PD-L1 expression in tumor cells, solid predominant histology, p53 aberrant expression, and PD-L1 expression in tumor-infiltrating immune cells are closely related. These variables should be considered when analyzing the clinical outcomes of patients with lung adenocarcinomas treated with anti-PD1/PD-L1 immune checkpoint inhibitors.

AB - Introduction: PD-L1 expression is a predictive biomarker for response to anti-programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) immune checkpoint inhibitors and can be evaluated by immunohistochemistry. Results of the clinicopathologic characteristics of PD-L1-positive lung adenocarcinoma have been inconsistent in previous studies, and there are no reports on the relationship between PD-L1 expression and p53 status in lung adenocarcinoma. Methods: We examined PD-L1 and p53 expression in a total of 323 surgically resected lung adenocarcinoma cases using anti-PD-L1 (clone SP142) and anti-p53 (clone DO-7) antibodies, and analyzed the clinicopathologic characteristics of PD-L1-positive cases and their relationship with p53 status. Results: PD-L1 expression in tumor cells was positive in 60 of 323 cases (18.6%). Higher PD-L1 expression (≥50%) was more prevalent in former or current smokers (p = 0.026) and was associated with more pack-years (p = 0.016). PD-L1-positive tumors were significantly associated with solid predominant type (p < 0.001), p53 aberrant expression (p < 0.001), and PD-L1 expression in tumor-infiltrating immune cells (p < 0.001). Patients with stage I to III tumors harboring PD-L1-positive tumor cells showed poor recurrence-free survival (p < 0.001) and overall survival (p < 0.001) on univariate analysis. Conclusions: PD-L1 expression in tumor cells, solid predominant histology, p53 aberrant expression, and PD-L1 expression in tumor-infiltrating immune cells are closely related. These variables should be considered when analyzing the clinical outcomes of patients with lung adenocarcinomas treated with anti-PD1/PD-L1 immune checkpoint inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=84964955489&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964955489&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2016.05.001

DO - 10.1016/j.lungcan.2016.05.001

M3 - Article

C2 - 27237031

AN - SCOPUS:84964955489

VL - 97

SP - 73

EP - 80

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

ER -